Home ivps4 2017-06-16T21:39:52+00:00

Investors Home

Achieve Life Sciences is a specialty pharmaceutical company committed to advancing cytisinicline as a smoking cessation aid to address the global tobacco and nicotine addiction epidemic.

Stock Info

Recent Press Releases

Recent News

Jun 29, 2020

Achieve Life Sciences Announces Pricing of $6 Million Registered Direct Offering

Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine...

Jun 29, 2020

Achieve Announces Successful Results from the Investigator-Initiated RAUORA Head-to-Head Non-Inferiority Clinical Trial Comparing Cytisinicline and Chantix® (varenicline) as a Treatment to Quit Smoking

Cytisinicline demonstrated quit rates at least as effective as varenicline Participants on cytisinicline experienced significantly fewer side effects than those on varenicline SEATTLE and...

May 14, 2020

Achieve Reports Financial Results for First Quarter 2020 and Provides Update on Cytisinicline Development Program

Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine...